Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

NCT05171972 · clinicaltrials.gov ↗

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Ofatumumab

Sponsor

University of Southern California

Collaborators

[object Object]